Creative Planning’s C4 Therapeutics CCCC Stock Holding History

Creative Planning’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$59.8K	Buy	+17,955	New	+$66.9K	﹤0.01%	4182

Other funds holding CCCC

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

Crestwood Advisors Group Boston, Massachusetts $6.76B AUM 24% 1-Year Est. Return

CV Advisors Aventura, Florida $594M AUM 18% 1-Year Est. Return

Achmea Investment Management Zeist, Netherlands $12.6B AUM 25.68% 1-Year Est. Return

Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return

Creative Planning's CCCC Position: Q3 2026 in Review

Creative Planning opened a new position in C4 Therapeutics (CCCC) in Q3 2026: 17,955 shares worth $59.8K. The stake represents ﹤0.01% of the portfolio and ranks #4182 among its holdings.

28 funds tracked by Wall St. Rank hold CCCC as of Q3 2026.

Creative Planning held 17,955 shares of C4 Therapeutics worth $59.8K as of Q3 2026.
C4 Therapeutics was a new Creative Planning position in Q3 2026.
C4 Therapeutics made up ﹤0.01% of Creative Planning's portfolio in Q3 2026, its #4182 holding.
28 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2026.

Based on Creative Planning's 13F filing for Q3 2026, filed 2 Nov 2026.